Literature DB >> 9844150

Long-term evolution of cardiomyopathy in dialysis patients.

R N Foley1, P S Parfrey, G M Kent, J D Harnett, D C Murray, P E Barre.   

Abstract

BACKGROUND: Left ventricular enlargement is very common at the inception of dialysis therapy, and highly predictive of future cardiac morbidity and mortality. It is not known whether cardiac size increases further while on dialysis therapy and whether potentially reversible risk factors for later progression can be identified. METHODS; Baseline and yearly echocardiograms were performed in a prospective inception cohort of 433 dialysis patients. The mean patient follow-up was 41 months; 29 patients had four consecutive echocardiograms at yearly intervals.
RESULTS: The patient subset with four echocardiograms was older (58 vs. 51 years, P = 0.02) and had a lower mass ventricular mass index (128 vs. 149 g/m2, P = 0.02) than the parent group. Using repeated measures analysis of variance, applied to those with four echocardiograms, there were progressive increases over time in posterior wall thickness (P = 0.015), left ventricular end-diastolic diameter, left ventricular mass index (P = 0.001), and cavity volume index (P = 0. 001). Mass-to-volume ratios did not change. The biggest changes in mass (18 g/m2 - 14%)and volume index (13 ml/m2 - 18%) occurred between baseline and year 1, although increases in both were seen after year 1. Hemodialysis versus peritoneal dialysis (41 g/m2, P = 0.008) and anemia (10 g/m2 per 1 g/dl drop in hemoglobin, P = 0.02) were associated with progressive left ventricular enlargement, but only within the first year of dialysis therapy. The left ventricular enlargement seen after year 1 was independent of anemia, blood pressure, serum albumin and mode of dialysis.
CONCLUSIONS: Progressive cardiac enlargement, particularly left ventricular dilation with compensatory hypertrophy, continues after starting dialysis therapy. Most of the additional cardiac enlargement seems to occur in the first year of dialysis therapy, suggesting that intervention beyond one year may be relatively ineffective.

Entities:  

Mesh:

Year:  1998        PMID: 9844150     DOI: 10.1046/j.1523-1755.1998.00154.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  36 in total

Review 1.  Current understanding of optimal blood pressure goals in dialysis patients.

Authors:  Paul Light
Journal:  Curr Hypertens Rep       Date:  2006-10       Impact factor: 5.369

Review 2.  Sudden cardiac death in chronic kidney disease: epidemiology and prevention.

Authors:  M Khaled Shamseddin; Patrick S Parfrey
Journal:  Nat Rev Nephrol       Date:  2011-02-01       Impact factor: 28.314

3.  The effect of a single haemodialysis session on functional mobility in older adults: a pilot study.

Authors:  Rebecca J A Sims; Rachel Taylor; Tahir Masud; Simon Roe; Michael J D Cassidy; Simon Mockett
Journal:  Int Urol Nephrol       Date:  2007-09-26       Impact factor: 2.370

4.  Oral anticoagulation with coumarins for patients with atrial fibrillation and chronic kidney disease?

Authors:  Walter H Hörl
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

5.  Severe cardiac hypertrophy and long-term dialysis: the Midwest Pediatric Nephrology Consortium study.

Authors:  Mark M Mitsnefes; Gina M Barletta; Ian G Dresner; Deepa H Chand; Denis Geary; Jen-Jar Lin; Hiren Patel
Journal:  Pediatr Nephrol       Date:  2006-06-29       Impact factor: 3.714

6.  CRIT-LINE: a noninvasive tool to monitor hemoglobin levels in pediatric hemodialysis patients.

Authors:  Rouba Garro; Scott Sutherland; Liz Bayes; Steven Alexander; Cynthia Wong
Journal:  Pediatr Nephrol       Date:  2015-04-09       Impact factor: 3.714

Review 7.  Management of cardiovascular disease in patients with kidney disease.

Authors:  Mark R Kahn; Michael J Robbins; Michael C Kim; Valentin Fuster
Journal:  Nat Rev Cardiol       Date:  2013-02-19       Impact factor: 32.419

8.  A longitudinal study of left ventricular function and structure from CKD to ESRD: the CRIC study.

Authors:  Nisha Bansal; Martin Keane; Patrice Delafontaine; Daniel Dries; Elyse Foster; Crystal A Gadegbeku; Alan S Go; L Lee Hamm; John W Kusek; Akinlolu O Ojo; Mahboob Rahman; Kaixiang Tao; Jackson T Wright; Dawei Xie; Chi-yuan Hsu
Journal:  Clin J Am Soc Nephrol       Date:  2013-02-14       Impact factor: 8.237

9.  Increased P wave dispersion and maximum P wave duration after hemodialysis.

Authors:  Ugur K Tezcan; Basri Amasyali; Ilknur Can; Kudret Aytemir; Sedat Köse; Izzet Yavuz; Hurkan Kursaklioglu; Ersoy Işik; Ertan Demirtaş; Ali Oto
Journal:  Ann Noninvasive Electrocardiol       Date:  2004-01       Impact factor: 1.468

Review 10.  Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis.

Authors:  Amarnath Marthi; Killian Donovan; Richard Haynes; David C Wheeler; Colin Baigent; Christopher M Rooney; Martin J Landray; Sharon M Moe; Jun Yang; Lisa Holland; Romina di Giuseppe; Annet Bouma-de Krijger; Borislava Mihaylova; William G Herrington
Journal:  J Am Soc Nephrol       Date:  2018-05-15       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.